Network origin in Frank DeRosa first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Subsidiary | Biotechnology | 23 | |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA.
19
| Subsidiary | Medical Specialties | 19 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Frank DeRosa via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BAXTER INTERNATIONAL INC. | Medical Specialties | Sales & Marketing | |
| BIOCRYST PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Sales & Marketing | |
| CHIMERIX, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PTC THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| DNIB UNWIND INC | Biotechnology | Chairman Corporate Officer/Principal | |
Proclara Biosciences, Inc.
 Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| SHIRE | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Nimbus Therapeutics LLC
 Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Biotechnology | Chairman Director/Board Member | |
Navitor Pharmaceuticals, Inc.
 Navitor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Virginia | College/University | Corporate Officer/Principal Graduate Degree | |
| Boston University | College/University | Undergraduate Degree Doctorate Degree | |
Shire US, Inc.
 Shire US, Inc. Medical DistributorsDistribution Services Shire US, Inc. sells and markets prescription medicines. The company was founded on September 28, 1983 and is headquartered in Lexington, MA. | Medical Distributors | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Consultant / Advisor Private Equity Investor | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Iowa State University | College/University | Undergraduate Degree Undergraduate Degree | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Doctorate Degree | |
| ACCURAY INCORPORATED | Medical Specialties | Sales & Marketing | |
| Denison University | College/University | Undergraduate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Undergraduate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| University of Massachusetts | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Worcester Polytechnic Institute | College/University | Masters Business Admin Undergraduate Degree Undergraduate Degree | |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Harvard Medical School | College/University | Corporate Officer/Principal Graduate Degree | |
Vifor Pharma Management AG
 Vifor Pharma Management AG Pharmaceuticals: MajorHealth Technology Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Chairman Director/Board Member Director/Board Member | |
| PROQR THERAPEUTICS N.V. | Pharmaceuticals: Major | Director/Board Member | |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
| IKENA ONCOLOGY, INC. | Biotechnology | Chairman Director/Board Member Chairman Director/Board Member | |
Alnylam Germany GmbH
 Alnylam Germany GmbH BiotechnologyHealth Technology Part of Alnylam Pharmaceuticals, Inc., Alnylam Germany GmbH is a company that is leading the translation of RNA Interference (RNAi) into a completely innovative class of medicines, which they believe have the potential to transform the lives of patients with genetic and rare diseases. The company is based in Munich, Germany. The CEOs of the company are David Ronald Jones, Hannes Schmeil, Theresa Marie Heggie. The text in the company's description is in German, but it appears to emphasize the importance of clinical trials in developing new medicines and highlights the company's use of RNAi technology to help patients with limited treatment options. | Biotechnology | Chief Executive Officer | |
Alnylam UK Ltd.
 Alnylam UK Ltd. BiotechnologyHealth Technology Founded in 2002, Alnylam UK Ltd. is a subsidiary of Alnylam Pharmaceuticals, Inc. that develops biotechnology products. The company is based in Maidenhead, UK. | Biotechnology | Director/Board Member | |
| FREELINE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chief Executive Officer | |
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Miscellaneous Commercial Services | Chairman Chief Executive Officer | |
| Sail Bio, Inc. | Director/Board Member Chief Executive Officer |
Statistics
International
| United States | 37 |
| United Kingdom | 5 |
| Switzerland | 4 |
| Germany | 3 |
| Ireland | 2 |
Sectoral
| Health Technology | 37 |
| Consumer Services | 10 |
| Finance | 3 |
| Distribution Services | 2 |
| Commercial Services | 2 |
Operational
| Director/Board Member | 167 |
| Corporate Officer/Principal | 131 |
| Independent Dir/Board Member | 62 |
| Chairman | 38 |
| Undergraduate Degree | 35 |
Most connected contacts
| Insiders | |
|---|---|
| Jean-Francois Formela | 47 |
| Daniel Lynch | 32 |
| Sylvie Grégoire | 25 |
| Ronald Renaud | 24 |
| Owen Hughes | 23 |
| Brian Gallagher | 20 |
| Suzanne Bruhn | 18 |
| Frédéric Chéreau | 17 |
| Theresa Heggie | 16 |
| Mark Rothera | 14 |
| Deanna M. Petersen | 14 |
| James G. Stout | 13 |
| Robert Meyer | 13 |
| Søren Tulstrup | 13 |
| John R. Schroer | 12 |
- Stock Market
- Insiders
- Frank DeRosa
- Company connections
